Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,346,081 | 2,029,911 | 1,200,622 | 808,662 | 2,048,477 |
| Depreciation Amortization | 4,916,560 | 3,571,229 | 2,347,992 | 1,218,779 | 5,190,044 |
| Accounts receivable | 555,940 | 48,678 | -42,588 | -138,369 | 1,132,917 |
| Accounts payable and accrued liabilities | -627,550 | -1,029,294 | -988,272 | -747,847 | 1,113,897 |
| Other Working Capital | -843,911 | -1,046,526 | -1,323,209 | -1,451,211 | 877,585 |
| Other Operating Activity | 883,835 | 1,278,589 | 1,003,140 | 958,642 | -367,285 |
| Operating Cash Flow | $7,230,955 | $4,852,587 | $2,197,685 | $648,656 | $9,995,635 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,033,743 | -744,137 | -513,547 | -324,101 | -1,080,789 |
| Net Acquisitions | 58,889 | N/A | N/A | N/A | -191,136 |
| Purchase Of Investment | -75,117 | -38,631 | -33,797 | -22,584 | -74,235 |
| Sale Of Investment | 164,680 | 145,926 | 132,480 | 47,571 | 150,597 |
| Purchase Sale Intangibles | -3,648,437 | -601,519 | -486,446 | -433,133 | -558,787 |
| Other Investing Activity | -3,607,263 | -560,289 | -462,960 | -430,184 | -567,750 |
| Investing Cash Flow | $-4,492,555 | $-1,197,131 | $-877,824 | $-729,298 | $-1,763,313 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 555,000 | N/A | N/A | N/A | 2,219,073 |
| Debt Repayment | -2,639,358 | -1,999,254 | -193,680 | -206,391 | -7,210,023 |
| Common Stock Repurchased | -199,275 | -191,196 | -193,889 | -207,353 | -690,026 |
| Dividend Paid | -2,067,678 | -1,909,879 | -1,008,050 | -992,322 | -2,524,618 |
| Other Financing Activity | -896,384 | -887,762 | -531,051 | -254,955 | -1,319,764 |
| Financing Cash Flow | $-5,247,695 | $-4,988,091 | $-1,926,670 | $-1,661,021 | $-9,525,358 |
| Exchange Rate Effect | 169,675 | 164,301 | 235,584 | 173,135 | 255,946 |
| Beginning Cash Position | 6,287,743 | 6,032,834 | 6,117,804 | 6,542,651 | 8,599,376 |
| End Cash Position | 3,948,122 | 4,864,501 | 5,746,586 | 4,974,131 | 7,562,286 |
| Net Cash Flow | $-2,339,621 | $-1,168,333 | $-371,218 | $-1,568,521 | $-1,037,090 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,230,955 | 4,852,587 | 2,197,685 | 648,656 | 9,995,635 |
| Capital Expenditure | -1,040,862 | -744,705 | -514,246 | -324,363 | -1,096,943 |
| Free Cash Flow | 6,190,093 | 4,107,882 | 1,683,439 | 324,293 | 8,898,692 |